JPMorgan Chase & Co. Boosts CME Group (NASDAQ:CME) Price Target to $252.00

Key Points

• JPMorgan Chase & Co. has raised its price target for CME Group from $246.00 to $252.00, indicating a potential downside of 4.70% from the stock's previous close.
• Multiple analysts have differing ratings and price targets for CME Group, with Piper Sandler setting a target of $296.00 and UBS Group lowering it to $285.00.
• Insider trading activity has been notable, with two insiders selling shares recently, leading to a decrease in their ownership stakes in the company.

CME Group (NASDAQ:CME - Get Free Report) had its target price raised by analysts at JPMorgan Chase & Co. from $246.00 to $252.00 in a report issued on Thursday,Benzinga reports. The firm currently has an "underweight" rating on the financial services provider's stock. JPMorgan Chase & Co.'s target price would indicate a potential downside of 4.70% from the stock's previous close.

Several other research analysts have also recently weighed in on the stock. Piper Sandler upped their price target on shares of CME Group from $283.00 to $296.00 and gave the stock an "overweight" rating in a report on Tuesday, July 15th. Barclays set a $298.00 price target on shares of CME Group and gave the stock an "equal weight" rating in a report on Thursday, July 24th. Oppenheimer upped their price target on shares of CME Group from $300.00 to $303.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. UBS Group reduced their target price on CME Group from $305.00 to $285.00 and set a "neutral" rating on the stock in a research note on Monday, September 8th. Finally, Wall Street Zen cut CME Group from a "hold" rating to a "sell" rating in a research note on Sunday, July 13th. Five research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $265.00.

CME Group Trading Up 0.9%

NASDAQ:CME opened at $264.43 on Thursday. The company has a market cap of $95.30 billion, a P/E ratio of 25.60, a P/E/G ratio of 4.74 and a beta of 0.43. The stock's fifty day moving average price is $271.14 and its two-hundred day moving average price is $270.75. CME Group has a 1 year low of $213.94 and a 1 year high of $290.79. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.02 and a quick ratio of 1.02.

CME Group (NASDAQ:CME - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The financial services provider reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.91 by $0.05. The firm had revenue of $1.69 billion for the quarter, compared to analysts' expectations of $1.68 billion. CME Group had a net margin of 58.48% and a return on equity of 14.60%. The business's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.56 earnings per share. As a group, analysts expect that CME Group will post 10.49 EPS for the current year.

Insider Activity

In other news, insider Timothy Francis Mccourt sold 379 shares of the firm's stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $259.83, for a total transaction of $98,475.57. Following the transaction, the insider directly owned 9,508 shares of the company's stock, valued at approximately $2,470,463.64. This trade represents a 3.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Sunil Cutinho sold 11,896 shares of the firm's stock in a transaction dated Tuesday, August 26th. The shares were sold at an average price of $271.47, for a total value of $3,229,407.12. Following the transaction, the insider directly owned 17,440 shares in the company, valued at $4,734,436.80. This trade represents a 40.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,043 shares of company stock valued at $3,527,956. 0.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Osaic Holdings Inc. grew its stake in shares of CME Group by 78.0% during the second quarter. Osaic Holdings Inc. now owns 53,675 shares of the financial services provider's stock valued at $14,683,000 after buying an additional 23,523 shares during the last quarter. Orion Porfolio Solutions LLC grew its stake in shares of CME Group by 10.0% during the second quarter. Orion Porfolio Solutions LLC now owns 15,094 shares of the financial services provider's stock valued at $4,160,000 after buying an additional 1,367 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in shares of CME Group by 138.0% during the second quarter. Thrivent Financial for Lutherans now owns 38,019 shares of the financial services provider's stock valued at $10,478,000 after buying an additional 22,046 shares during the last quarter. MASTERINVEST Kapitalanlage GmbH bought a new stake in shares of CME Group in the second quarter worth about $9,084,000. Finally, Stance Capital LLC purchased a new position in CME Group during the 2nd quarter valued at about $1,330,000. 87.75% of the stock is owned by institutional investors.

CME Group Company Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.